JP2008543915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543915A5 JP2008543915A5 JP2008517496A JP2008517496A JP2008543915A5 JP 2008543915 A5 JP2008543915 A5 JP 2008543915A5 JP 2008517496 A JP2008517496 A JP 2008517496A JP 2008517496 A JP2008517496 A JP 2008517496A JP 2008543915 A5 JP2008543915 A5 JP 2008543915A5
- Authority
- JP
- Japan
- Prior art keywords
- benzimidazol
- trifluoromethyl
- aniline
- disease
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- QNRAJGGNCAPFND-UHFFFAOYSA-N 3-(1h-benzimidazol-2-ylamino)benzonitrile Chemical compound N#CC1=CC=CC(NC=2NC3=CC=CC=C3N=2)=C1 QNRAJGGNCAPFND-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- BNEMVIZLWMJXMF-UHFFFAOYSA-N n-(2,3,4-trifluorophenyl)-1h-benzimidazol-2-amine Chemical compound FC1=C(F)C(F)=CC=C1NC1=NC2=CC=CC=C2N1 BNEMVIZLWMJXMF-UHFFFAOYSA-N 0.000 claims 1
- CVIMPJVXTIFPDR-UHFFFAOYSA-N n-(2-phenylphenyl)-1h-benzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2NC=1NC1=CC=CC=C1C1=CC=CC=C1 CVIMPJVXTIFPDR-UHFFFAOYSA-N 0.000 claims 1
- WJMDSPCWFQLKIN-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-1h-benzimidazol-2-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1NC1=NC2=CC=CC=C2N1 WJMDSPCWFQLKIN-UHFFFAOYSA-N 0.000 claims 1
- FICZTJWYAFBGBP-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-n-methyl-1h-benzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2NC=1N(C)C1=CC=C(Cl)C(Cl)=C1 FICZTJWYAFBGBP-UHFFFAOYSA-N 0.000 claims 1
- WSZXVQQZOGCKDD-UHFFFAOYSA-N n-(3,4-difluorophenyl)-1h-benzimidazol-2-amine Chemical compound C1=C(F)C(F)=CC=C1NC1=NC2=CC=CC=C2N1 WSZXVQQZOGCKDD-UHFFFAOYSA-N 0.000 claims 1
- XRWUVKRSWJWCFJ-UHFFFAOYSA-N n-(3,5-dichlorophenyl)-1h-benzimidazol-2-amine Chemical compound ClC1=CC(Cl)=CC(NC=2NC3=CC=CC=C3N=2)=C1 XRWUVKRSWJWCFJ-UHFFFAOYSA-N 0.000 claims 1
- VDELLUVTWLBIHA-UHFFFAOYSA-N n-(3,5-difluorophenyl)-1h-benzimidazol-2-amine Chemical compound FC1=CC(F)=CC(NC=2NC3=CC=CC=C3N=2)=C1 VDELLUVTWLBIHA-UHFFFAOYSA-N 0.000 claims 1
- DESWOWLTWCOBOI-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-1h-benzimidazol-2-amine Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC2=CC=CC=C2N1 DESWOWLTWCOBOI-UHFFFAOYSA-N 0.000 claims 1
- XSAWUTHHNIJKRI-UHFFFAOYSA-N n-(3-chlorophenyl)-1h-benzimidazol-2-amine Chemical compound ClC1=CC=CC(NC=2NC3=CC=CC=C3N=2)=C1 XSAWUTHHNIJKRI-UHFFFAOYSA-N 0.000 claims 1
- ATZIHMHTBDVWPP-UHFFFAOYSA-N n-(4-chlorophenyl)-1h-benzimidazol-2-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC2=CC=CC=C2N1 ATZIHMHTBDVWPP-UHFFFAOYSA-N 0.000 claims 1
- LLXCHOGIKFCMMS-UHFFFAOYSA-N n-(4-fluoro-3-methylphenyl)-1h-benzimidazol-2-amine Chemical compound C1=C(F)C(C)=CC(NC=2NC3=CC=CC=C3N=2)=C1 LLXCHOGIKFCMMS-UHFFFAOYSA-N 0.000 claims 1
- JCPBVJDSLDBKSJ-UHFFFAOYSA-N n-(4-fluorophenyl)-1h-benzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC2=CC=CC=C2N1 JCPBVJDSLDBKSJ-UHFFFAOYSA-N 0.000 claims 1
- AWWPEZUTCHDUPP-UHFFFAOYSA-N n-(4-propan-2-ylphenyl)-1h-benzimidazol-2-amine Chemical compound C1=CC(C(C)C)=CC=C1NC1=NC2=CC=CC=C2N1 AWWPEZUTCHDUPP-UHFFFAOYSA-N 0.000 claims 1
- TWDAYWOIVWKCFV-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound FC(F)(F)C1=CC=C(Cl)C(NC=2NC3=CC=CC=C3N=2)=C1 TWDAYWOIVWKCFV-UHFFFAOYSA-N 0.000 claims 1
- IWQDFOADKFVOHQ-UHFFFAOYSA-N n-[2-fluoro-3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1NC1=NC2=CC=CC=C2N1 IWQDFOADKFVOHQ-UHFFFAOYSA-N 0.000 claims 1
- JTVYHMYOFWSBIR-UHFFFAOYSA-N n-[2-methyl-3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC2=CC=CC=C2N1 JTVYHMYOFWSBIR-UHFFFAOYSA-N 0.000 claims 1
- NNINUTMAMXDIMK-UHFFFAOYSA-N n-[2-methyl-5-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound CC1=CC=C(C(F)(F)F)C=C1NC1=NC2=CC=CC=C2N1 NNINUTMAMXDIMK-UHFFFAOYSA-N 0.000 claims 1
- LPKCYASSIJNCKT-UHFFFAOYSA-N n-[3,5-bis(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(NC=2NC3=CC=CC=C3N=2)=C1 LPKCYASSIJNCKT-UHFFFAOYSA-N 0.000 claims 1
- OZSXMCLVXAYZLJ-UHFFFAOYSA-N n-[3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound FC(F)(F)C1=CC=CC(NC=2NC3=CC=CC=C3N=2)=C1 OZSXMCLVXAYZLJ-UHFFFAOYSA-N 0.000 claims 1
- GEDXUWWRIKYXEH-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound FC(F)(F)C1=CC(F)=CC(NC=2NC3=CC=CC=C3N=2)=C1 GEDXUWWRIKYXEH-UHFFFAOYSA-N 0.000 claims 1
- OHFXBBPZGSIOAQ-UHFFFAOYSA-N n-[3-methoxy-5-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound FC(F)(F)C1=CC(OC)=CC(NC=2NC3=CC=CC=C3N=2)=C1 OHFXBBPZGSIOAQ-UHFFFAOYSA-N 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- PSCVLYRDOWNMOM-UHFFFAOYSA-N n-[4-(trifluoromethoxy)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=NC2=CC=CC=C2N1 PSCVLYRDOWNMOM-UHFFFAOYSA-N 0.000 claims 1
- FKOYGKNNSVQCPM-UHFFFAOYSA-N n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1NC1=NC2=CC=CC=C2N1 FKOYGKNNSVQCPM-UHFFFAOYSA-N 0.000 claims 1
- JIUDYVPMTLQYPA-UHFFFAOYSA-N n-[4-bromo-3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=C(Br)C(C(F)(F)F)=CC(NC=2NC3=CC=CC=C3N=2)=C1 JIUDYVPMTLQYPA-UHFFFAOYSA-N 0.000 claims 1
- GVORIUUNVSHUSR-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC=2NC3=CC=CC=C3N=2)=C1 GVORIUUNVSHUSR-UHFFFAOYSA-N 0.000 claims 1
- SVBRYJZTSPUETP-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1NC1=NC2=CC=CC=C2N1 SVBRYJZTSPUETP-UHFFFAOYSA-N 0.000 claims 1
- HORZXLXFCUFEOK-UHFFFAOYSA-N n-[4-methyl-3-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1NC1=NC2=CC=CC=C2N1 HORZXLXFCUFEOK-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69225205P | 2005-06-21 | 2005-06-21 | |
| DKPA200500910 | 2005-06-21 | ||
| PCT/EP2006/063405 WO2006136580A2 (en) | 2005-06-21 | 2006-06-21 | 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543915A JP2008543915A (ja) | 2008-12-04 |
| JP2008543915A5 true JP2008543915A5 (cg-RX-API-DMAC7.html) | 2009-07-23 |
Family
ID=37526982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517496A Abandoned JP2008543915A (ja) | 2005-06-21 | 2006-06-21 | ２−（フェニルアミノ）ベンズイミダゾール誘導体及び低コンダクタンスカルシウム依存性カリウムチャネルのモジュレーターとしてのそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7960561B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1896427A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008543915A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2612922A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007015689A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006136580A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0715103D0 (en) * | 2007-08-03 | 2007-09-12 | Lectus Therapeutics Ltd | Calcium ion channel modulators and uses thereof |
| CA3207643A1 (en) | 2015-09-23 | 2017-03-30 | XWPharma Ltd. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
| EP3419973B1 (en) * | 2016-02-24 | 2020-04-08 | Acesion Pharma ApS | Novel potassium channel inhibitors |
| WO2017160922A1 (en) * | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| BR112019020464A2 (pt) | 2017-03-30 | 2020-04-28 | Xw Laboratories Inc. | compostos derivados de heteroarila bicíclica, composição farmacêutica compreendendo os ditos compostos, adesivo transdérmico compreendendo a dita composição e uso terapêutico dos compostos e composição |
| US11168074B2 (en) * | 2017-08-23 | 2021-11-09 | Acesion Pharma Aps | Potassium channel inhibitors |
| ES2947089T3 (es) | 2018-09-30 | 2023-08-01 | Xwpharma Ltd | Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos |
| WO2021127461A1 (en) | 2019-12-20 | 2021-06-24 | Xw Laboratories Limited | Methods of synthesizing 4-valyloxybutyric acid |
| KR20230008190A (ko) | 2020-06-18 | 2023-01-13 | 엑스더블유파마 리미티드 | 수용성 원료의약품의 약학적 과립화제 |
| AU2021292406B2 (en) | 2020-06-18 | 2024-03-14 | XWPharma Ltd. | Controlled release granulations of water-soluble active pharmaceutical ingredients |
| WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
| AU2021357705B2 (en) | 2020-10-05 | 2024-09-26 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
| EP4308086B1 (en) | 2021-03-19 | 2025-10-15 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE632578A (cg-RX-API-DMAC7.html) * | 1963-05-22 | |||
| GB1171904A (en) * | 1965-10-21 | 1969-11-26 | Unilever Ltd | Anilinobenzimidazoles having Antibacterial Properties |
| JP2869561B2 (ja) | 1989-05-22 | 1999-03-10 | 大塚製薬株式会社 | 血小板粘着抑制剤 |
| WO1998040381A1 (en) * | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| DE10060292A1 (de) * | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
| WO2003043345A1 (fr) | 2001-11-16 | 2003-05-22 | Ntt Docomo, Inc. | Procede de codage d'image, procede de decodage d'image, codeur et decodeur d'image, programme, signal de donnees informatiques et systeme d'emission d'image |
| DE10304294A1 (de) * | 2003-02-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | N-Substituierte(Benzoimidazol-2-yl)-phenyl, Verfahren zu ihrer Herstellung , ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US20050054705A1 (en) | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| WO2004098494A2 (en) | 2003-04-30 | 2004-11-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1677791A4 (en) | 2003-10-31 | 2007-08-15 | Takeda Pharmaceutical | NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS |
-
2006
- 2006-06-21 US US11/919,708 patent/US7960561B2/en not_active Expired - Fee Related
- 2006-06-21 WO PCT/EP2006/063405 patent/WO2006136580A2/en not_active Ceased
- 2006-06-21 EP EP06777399A patent/EP1896427A2/en not_active Withdrawn
- 2006-06-21 JP JP2008517496A patent/JP2008543915A/ja not_active Abandoned
- 2006-06-21 CA CA002612922A patent/CA2612922A1/en not_active Abandoned
- 2006-06-21 MX MX2007015689A patent/MX2007015689A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543915A5 (cg-RX-API-DMAC7.html) | ||
| JP2008526815A5 (cg-RX-API-DMAC7.html) | ||
| JP5016583B2 (ja) | アミノピリミジン化合物製造の原料化合物とその製造方法 | |
| CN101014564B (zh) | 用于治疗呼吸系统疾病的取代酸 | |
| TWI409247B (zh) | ４-取代之苯氧基苯基乙酸衍生物 | |
| CN1039492C (zh) | 羰基取代的含氮杂环及其制法、中间体、组合物和应用 | |
| JP2012515209A5 (cg-RX-API-DMAC7.html) | ||
| CN1291184A (zh) | 环烯衍生物、其制造方法和用途 | |
| AU2003262805A1 (en) | Acetophenone potentiators of metabotropic glutamate receptors | |
| CN1137878C (zh) | 芳氧基苯胺衍生物 | |
| JP2012523440A5 (cg-RX-API-DMAC7.html) | ||
| JP2007509043A5 (cg-RX-API-DMAC7.html) | ||
| WO2000066584B1 (fr) | 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES ET/OU -5-THIONES INHIBITRICES DE PHOSPHODIESTERASES IV | |
| US20070287716A1 (en) | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors | |
| AU2136099A (en) | Aniline derivatives possessing an inhibitory effect of nitric oxide synthase | |
| WO2010011917A1 (en) | SEH AND 11β-HSD1 DUAL INHIBITORS | |
| CN104884427A (zh) | 可用于合成苯甲酰胺化合物的化合物 | |
| IL235097A (en) | History of insulin-2 and as protein kinase inhibitors | |
| JP2013544797A5 (cg-RX-API-DMAC7.html) | ||
| JP2010502674A5 (cg-RX-API-DMAC7.html) | ||
| JP2009542602A5 (cg-RX-API-DMAC7.html) | ||
| JP2012505183A (ja) | 光学活性（ｓ）−（−）−２−（ｎ−プロピルアミノ）−５−メトキシテトラリン及び（ｓ）−（−）−２−（ｎ−プロピルアミノ）−５−ヒドロキシテトラリン化合物の調製の方法 | |
| JP2009530352A5 (cg-RX-API-DMAC7.html) | ||
| JP2009511548A5 (cg-RX-API-DMAC7.html) | ||
| CA2562114A1 (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders |